

Predictors for successful treatment outcome in patients with comorbid attention-deficit/hyperactivity disorder (ADHD) and substance use disorder (SUD): an international observational cohort study

Submission date 20/12/2019	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 06/02/2020	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 09/02/2026	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Patients with substance use disorder (SUD) are three to four times more likely to have attention deficit/hyperactivity disorder (ADHD) compared to the general population. Standard treatments for ADHD has not proven to be as effective in comorbid patients as in patients with ADHD only. There is currently a lack of knowledge of how to best treat patients with comorbid ADHD-SUD.

The purpose of this study is to gain more knowledge regarding treatments provided, and treatment outcome for patients with ADHD and substance use disorder. The study is observational and the aim is to describe the natural course of the disorders, and to identify factors that might predict a successful treatment result, i.e. retention to treatment and reduction in ADHD and SUD symptoms.

Who can participate?

This study will invite 600 adult (≥ 18 years) treatment seeking patients with comorbid ADHD and SUD.

What does the study involve?

Participants will be asked for informed consent to provide self-reported data at the start of treatment, and after 3 and 9 months, respectively. Data from the patient files will be collected, e.g. to confirm whether a patient is still in treatment or not.

What are the possible benefits and risks of participating?

This a naturalistic study, observational study and participation does not affect the participants treatment in any way. Participants will not receive any compensation.

Where is the study run from?

The study is a multicentre international study from different countries in Europe, USA and Australia.

When is the study starting and how long is it expected to run for?

The study is anticipated to go on between June 2017 and May 2022

Who is funding the study?

Investigator initiated and funded

Who is the main contact?

Christoffer Brynte

Physician, Stockholm Centre for Dependency Disorders

PhD student, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm

Christoffer.brynte@ki.se

Contact information

Type(s)

Scientific

Contact name

Prof Johan Franck

Contact details

Friskvårdsvägen 4, plan 2

S:t Göran

Stockholm

Sweden

11281

+46 (0)8 123 400 00

johan.franck@ki.se

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Nil known

Study information

Scientific Title

INCAS: International Naturalistic Cohort Study of ADHD and Substance Use Disorders Study

Acronym

INCAS

Study objectives

The primary aim of the study is descriptive rather than hypothesis driven: To investigate the treatment modalities provided to individuals with comorbid ADHD/SUD who are currently in treatment at SUD treatment services, and to identify predictors for successful treatment outcomes, as measured by retention, substance use and ADHD symptoms.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 16/06/2017, Swedish Ethical Review Authority (Etikprövningsmyndigheten, Box 2110, 750 02, Uppsala, Sweden; +46 10-475 08 00; registrator@etikprovning.se), ref: 2017/973-32

Study design

Naturalistic multicenter observational cohort study

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Attention deficit hyperactivity/impulsivity disorder with comorbid substance use disorder

Interventions

This study is non-interventional and investigates the treatment modalities provided to the study population at the participating treatment services.

This study will invite 600 treatment-seeking patients from different countries in Europe, USA and Australia to participate for 9 months. Participants will be asked for informed consent to provide self-reported data at the start of treatment, and after 3 and 9 months, respectively. Data from the patient files will be collected, e.g. to confirm whether a patient is still in treatment or not. This is a naturalistic study, observational study and participation does not affect the participants' treatment in any way.

Intervention Type

Other

Primary outcome(s)

1. Retention to treatment, defined as time to drop-out (last contact between patient and treatment center)
2. ADHD symptoms measured using the Adult ADHD Self-Report Scale (ASRS) at 3 months follow-up
3. Number of days with heavy alcohol use or days with illicit drug use during the last 30 days, measured using the Time-Line Follow-Back instrument at 3 months follow-up

Key secondary outcome(s)

1. ADHD symptoms measured using the adult ASRS at 9 months follow-up
2. Substance use measured with TLFB, defined as the number of days with heavy alcohol use or days with illicit drug use the last 30 days at 9 months follow-up.
3. ADHD symptoms according to the Expanded Adult ADHD Self-Report Scale at 3 and 9 months follow-up, respectively
4. Employment measured using questionnaire and patient files at baseline, 3 months and 9 months
5. Number of accidents as reported by the participant using questionnaire and patient files at baseline, 3 months and 9 months
6. Days with any alcohol use during the last 30 days measured using Timeline Follow-Back interview at baseline, 3 months and 9 months follow-up

Completion date

31/05/2022

Eligibility

Key inclusion criteria

1. Men and women ≥ 18 years of age seeking treatment for SUD at any of the participating sites
2. ADHD diagnosis according to DSM-5
3. SUD diagnosis (DSM-5 moderate to severe, ICD-10 dependence)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

100 years

Sex

All

Total final enrolment

578

Key exclusion criteria

There are no formal exclusion criteria except incapability to complete the assessments

Date of first enrolment

01/07/2017

Date of final enrolment

30/06/2021

Locations**Countries of recruitment**

Australia

Belgium

France

Germany

Hungary

Netherlands

Spain

Sweden

Switzerland

United States of America

Study participating centre**Stockholm Centre for Dependency Disorders**

Friskvårdsvägen 4, plan 2, St:Göran

Stockholm

Sweden

112 81

Study participating centre**Multiversum Boechout, Cadenza 2**

Provinciesteenweg 408

Antwerpen

Belgium

2530 Boechout

Study participating centre**Nyíró Gyula National Institute of Psychiatry and Addictions**

Jász street 14

Budapest
Hungary
1135

Study participating centre

De Hoop ggz
Provincialeweg 70
Dordrecht
Netherlands
3329

Study participating centre

UPD Bern
Bolligenstrasse 111
3000 Bern 60
Switzerland
3000 Bern 60

Study participating centre

Novadik-Kentron
Hogedwarsstraat 3
Vught
Netherlands
5261 LX

Study participating centre

Tactus verslavingszorg
Linie 612
Apeldoorn,
Netherlands
7325 DZ

Sponsor information

Organisation

Beroendecentrum Stockholm

ROR

<https://ror.org/04g380834>

Funder(s)

Funder type

Other

Funder Name

Investigator initiated and funded

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		23/12/2024	17/01/2025	Yes	No
Results article		06/02/2026	09/02/2026	Yes	No
Protocol article		23/09/2022	29/09/2022	Yes	No
Protocol file			11/05/2021	No	No